glp-1 long-term safety Your journey is unique, but here's a peek at what typically happens over time ⏳ For Important Information about GLP-1 medications, including Boxed Warning, go to ro.co/safety #weightloss #newyearnewme #weightlosstransformation # The GLP-1 Trap: Your Jumpstart

doi: 10.1016/j.neuropharm.2014.07.015 158 McCleanPLHlscherC

Seeing the scale go up is not a sign of failure

& Schroder, K

Figure 1: FDA Approved Incretin Mimetic (GLP-1 and dual agonist) Diabetes and Obesity Products (as of December 2023) The Future of Incretin Mimetics in Diabetes and Obesity Looking Forward GLP-1 Clinical Development Pipeline Looking Forward GLP-1 Clinical Development Pipeline While Novo Nordisk and Eli Lilly dominate todays market, the success of incretin mimetics has attracted greater interest and investment, with a slew of potential new players aiming to enter and carve out their own space

Pharmaceutical companies have been trying to produce small-molecule GLP-1 agonists that are shelf-stable and can be taken orallyfor instance, Pfizer and Eli Lilly have developed Danuglipron and Orforglipron, respectivelybut we know very little about how they work, said Ali Gler, a neuroscientist at the University of Virginia

Pricing dynamics reflect unit values, freight costs, exchange rates, and regulatory shifts that affect sourcing decisions